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Background
Adenoid cystic carcinoma (ACC) is among the most
common malignant salivary gland tumors. Approximately
50% of patients develop distant metastases and up to one
third die within 2 years. Chemotherapy provides limited
benefit, and is not associated with a survival advantage.
Radiotherapy is standard for localized disease, and is also
commonly used for palliation of symptomatic metastases.
Little is known about endogenous immune responses
directed against ACC at baseline, or following conven-
tional treatments. Therefore, we evaluated ACC speci-
mens for infiltrating immune cells and expression of
immune checkpoint ligands PD-L1 and PD-L2 and their
receptor, PD-1, to guide future investigations of immu-
notherapy in ACC patients.
Methods
We retrospectively obtained whole-tissue slides from ACC
patients, and prospectively collected serial tissue, serum
and saliva samples from one patient treated with concur-
rent chemoradiation therapy with residual tumor after
treatment. Hematoxylin/eosin and immunohistochemical
staining was performed using immunologic markers
including: CD4, CD8, FoxP3, PD-1, PD-L1, and PD-L2.
Multiple areas from stained slides were evaluated and
scored by a pathologist. We also evaluated the patient
treated with chemoradiation for potential anti-tumor anti-
body responses before and after treatment using ProtoAr-
ray Immune Response Profiling (Invitrogen).
Results
Tissue from 28 primary and metastatic ACC deposits were
obtained from 20 patients. Most tumors demonstrated
only mild/modest numbers of infiltrating immune cells
(< 100/HPF, n=18; 64%); in the majority of other tumors,
infiltrating immune cells demonstrated high levels of
PD-L1 expression. ACC cells did not express PD-L1.
Seventeen ACC deposits demonstrated PD-L2 expression
(61%). PD-L2 was expressed in 53% of primary lesions
(n=9), and 67% of metastatic deposits (n=8). Comparing
the ACC tumor before and after chemoradiation,
we found increased CD8+ T cells (34 compared with 110/
HPF), and decreased FOXP3+ regulatory cells (104 com-
pared with 33/HPF). After chemoradiation, proteomic
analysis revealed increased titers of multiple antibodies in
both serum and saliva directed against potential tumor
antigens.
Conclusions
We profiled the immunologic microenvironment in both
primary and matching metastatic ACC’s. Most ACC
demonstrate only mild/modest numbers of tumor infil-
trating immune cells. PD-L1 expression was limited to
immune cells and not ACC tumor cells. In contrast,
PD-L2 was expressed on tumor cells in the majority of
cases. Following treatment, a patient who received che-
moradiation demonstrated increased CD8+ T cells,
decreased FOXP3+ regulatory T cells, and potential evi-
dence of a more robust anti-tumor antibody response.
These data suggest that PD-1 inhibition, potentially in
combination with conventional treatments, could repre-
sent a promising treatment strategy for patients with
ACC.
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